Canadian Kidney Transplant Recipients', Transplant Candidates', and Caregivers' Perspectives on Precision Medicine and Molecular Matching in Kidney Allocation: A Qualitative Analysis.

IF 1.5 Q3 UROLOGY & NEPHROLOGY
Canadian Journal of Kidney Health and Disease Pub Date : 2025-05-23 eCollection Date: 2025-01-01 DOI:10.1177/20543581251342440
Fabian Ballesteros, Aliya Affdal, Mohamad Issa, Marie-Françoise Malo, Savannah-Lou Cochran-Mavrikakis, Carina Sancho, Stirling Bryan, Paul Keown, Ruth Sapir-Pichhadze, Marie-Chantal Fortin
{"title":"Canadian Kidney Transplant Recipients', Transplant Candidates', and Caregivers' Perspectives on Precision Medicine and Molecular Matching in Kidney Allocation: A Qualitative Analysis.","authors":"Fabian Ballesteros, Aliya Affdal, Mohamad Issa, Marie-Françoise Malo, Savannah-Lou Cochran-Mavrikakis, Carina Sancho, Stirling Bryan, Paul Keown, Ruth Sapir-Pichhadze, Marie-Chantal Fortin","doi":"10.1177/20543581251342440","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antibody-mediated rejection (AMR) is an important cause of kidney transplant loss. A new strategy requiring application of precision medicine tools in transplantation considers molecular compatibility between donors and recipients and holds the promise of improved immunologic risk, preventing rejection and premature graft loss.</p><p><strong>Objective: </strong>The objective of this study was to gather patients' and caregivers' perspectives on molecular compatibility in kidney transplantation.</p><p><strong>Design: </strong>Individual semi-structured interviews.</p><p><strong>Setting: </strong>The Centre hospitalier de l'Université de Montréal (CHUM) and McGill University Health Centre (MUHC) kidney transplant programs.</p><p><strong>Participants: </strong>Kidney transplant candidates, kidney transplant recipients, and caregivers.</p><p><strong>Methods: </strong>Twenty-seven participants took part in semi-structured interviews between July 2020 and November 2021. The interviews were digitally recorded, transcribed, and analyzed using the qualitative description approach.</p><p><strong>Results: </strong>Participants had different levels of knowledge about the kidney allocation process. They expressed trust in the system and healthcare professionals. They indicated that a fair organ allocation system should strive to maximize graft survival as it would decrease the demand for deceased donor kidneys and allow more patients to access transplantation. Molecular matching and precision medicine were seen as important improvements in the kidney transplant allocation process given their potential to improve graft survival and decrease the need for retransplantation. However, participants were concerned about increased waiting times that may negatively impact some patients upon implementation of molecular matching. To address these concerns, participants suggested integrating safeguards in the form of maximum waiting time for molecularly matched kidneys.</p><p><strong>Limitations: </strong>This study was conducted in the province of Quebec most of the participants were white and highly educated. Consequently, the results could not be generalizable to other populations, including ethnic minorities.</p><p><strong>Conclusions: </strong>Molecular matching and precision medicine are viewed as promising technologies for decreasing the incidence of AMR and improving graft survival. However, further studies are needed to determine how to ethically integrate this technology into the kidney allocation scheme.</p><p><strong>Trial registration: </strong>Not registered.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"12 ","pages":"20543581251342440"},"PeriodicalIF":1.5000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102556/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Kidney Health and Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20543581251342440","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Antibody-mediated rejection (AMR) is an important cause of kidney transplant loss. A new strategy requiring application of precision medicine tools in transplantation considers molecular compatibility between donors and recipients and holds the promise of improved immunologic risk, preventing rejection and premature graft loss.

Objective: The objective of this study was to gather patients' and caregivers' perspectives on molecular compatibility in kidney transplantation.

Design: Individual semi-structured interviews.

Setting: The Centre hospitalier de l'Université de Montréal (CHUM) and McGill University Health Centre (MUHC) kidney transplant programs.

Participants: Kidney transplant candidates, kidney transplant recipients, and caregivers.

Methods: Twenty-seven participants took part in semi-structured interviews between July 2020 and November 2021. The interviews were digitally recorded, transcribed, and analyzed using the qualitative description approach.

Results: Participants had different levels of knowledge about the kidney allocation process. They expressed trust in the system and healthcare professionals. They indicated that a fair organ allocation system should strive to maximize graft survival as it would decrease the demand for deceased donor kidneys and allow more patients to access transplantation. Molecular matching and precision medicine were seen as important improvements in the kidney transplant allocation process given their potential to improve graft survival and decrease the need for retransplantation. However, participants were concerned about increased waiting times that may negatively impact some patients upon implementation of molecular matching. To address these concerns, participants suggested integrating safeguards in the form of maximum waiting time for molecularly matched kidneys.

Limitations: This study was conducted in the province of Quebec most of the participants were white and highly educated. Consequently, the results could not be generalizable to other populations, including ethnic minorities.

Conclusions: Molecular matching and precision medicine are viewed as promising technologies for decreasing the incidence of AMR and improving graft survival. However, further studies are needed to determine how to ethically integrate this technology into the kidney allocation scheme.

Trial registration: Not registered.

Abstract Image

Abstract Image

Abstract Image

加拿大肾移植受者、移植候选人和护理人员对精准医学和分子匹配在肾脏分配中的观点:一项定性分析。
背景:抗体介导的排斥反应(AMR)是肾移植损失的重要原因。一种新的策略需要在移植中应用精确医学工具,考虑供体和受体之间的分子相容性,并有望改善免疫风险,防止排斥和移植过早丢失。目的:本研究的目的是收集患者和护理人员对肾移植分子相容性的看法。设计:单独的半结构化访谈。环境:蒙特里萨大学医院中心(CHUM)和麦吉尔大学健康中心(MUHC)肾移植项目。参与者:肾移植候选人、肾移植受者和护理人员。方法:在2020年7月至2021年11月期间,对27名参与者进行半结构化访谈。访谈以数字方式记录、转录,并使用定性描述方法进行分析。结果:参与者对肾脏分配过程有不同程度的了解。他们表达了对医疗系统和医疗专业人员的信任。他们指出,一个公平的器官分配系统应该努力使移植物存活最大化,因为这将减少对已故供体肾脏的需求,并允许更多的患者接受移植。分子匹配和精准医学被视为肾移植分配过程的重要改进,因为它们有可能提高移植物的存活率并减少再次移植的需要。然而,参与者担心等待时间的增加可能会对一些患者实施分子匹配产生负面影响。为了解决这些问题,与会者建议以分子匹配肾脏的最长等待时间的形式整合保障措施。局限性:这项研究是在魁北克省进行的,大多数参与者是受过高等教育的白人。因此,研究结果不能推广到其他人群,包括少数民族。结论:分子匹配和精准医疗是降低AMR发生率和提高移植物存活率的有前途的技术。然而,需要进一步的研究来确定如何在伦理上将这项技术整合到肾脏分配方案中。试验注册:未注册。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.00
自引率
5.90%
发文量
84
审稿时长
12 weeks
期刊介绍: Canadian Journal of Kidney Health and Disease, the official journal of the Canadian Society of Nephrology, is an open access, peer-reviewed online journal that encourages high quality submissions focused on clinical, translational and health services delivery research in the field of chronic kidney disease, dialysis, kidney transplantation and organ donation. Our mandate is to promote and advocate for kidney health as it impacts national and international communities. Basic science, translational studies and clinical studies will be peer reviewed and processed by an Editorial Board comprised of geographically diverse Canadian and international nephrologists, internists and allied health professionals; this Editorial Board is mandated to ensure highest quality publications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信